Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LXR-623 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| LXR-623 | DRUG | - |
Inclusion: * Healthy, men or women, aged 19-50 years Exlcusion: * Use of any investigational or prescription drug within 30 days before study start * Any clinically imprtant medical disease or abnormal laboratory test results
LXR-623 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and remains in clinical development. The completed Phase 1 trials evaluated the drug in healthy subjects in the United States and healthy Japanese adults in Japan.
LXR-623 is being developed by Pfizer, Inc. (NYSE: PFE). The company sponsored the Phase 1 clinical trials of this investigational small molecule.
LXR-623 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials in healthy volunteers have been completed.
LXR-623 has two completed Phase 1 trials: NCT00366522, a study in healthy subjects in the United States, and NCT00385489, a study in healthy Japanese adult males in Japan. Both trials were completed and enrolled healthy volunteers.
LXR-623 is not FDA approved. It is an investigational small molecule that has only been studied in Phase 1 clinical trials with healthy volunteers. No approval status has been established for this drug.